1 / 35

BIOLOGY of COMPLEMENT

BIOLOGY of COMPLEMENT. COMPLEMENT. DIAGNOSIS. BIOLOGY. =. C4d. C3. injury. =. C4 d. =. C3. injury. C4 d. MBL. CRP. Apoptotic. CMV cells. =. C3. injury. C4 d. MBL. Regulators. CRP. Apoptotic. CMV cells. protection. =. C3. injury. C4 d. MBL. Regulators. CRP.

bsullins
Download Presentation

BIOLOGY of COMPLEMENT

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. BIOLOGY of COMPLEMENT

  2. COMPLEMENT DIAGNOSIS BIOLOGY

  3. = C4d

  4. C3 injury = C4d

  5. = C3 injury C4d MBL CRP Apoptotic CMV cells

  6. = C3 injury C4d MBL Regulators CRP Apoptotic CMV cells

  7. protection = C3 injury C4d MBL Regulators CRP Apoptotic CMV cells

  8. Three Pathways of Complement Activation Classical C1 C4 Lectin C2 C5 C3 MBL B Alternative

  9. Three Pathways of Complement Activation Classical C1 C4 b a a Lectin C2 C5 C3 b b a MBL a B b Alternative

  10. C4bC2a C3bBb C3 C4 C1 C2 C5 C6 C7 C8 C9 0.6 mg/ml 1.3 mg/ml

  11. C4bp DAF CR1 Factor I MCP Factor H DAF CR1 Factor I C4bp CR1 Factor I Vitronectin MCP Clusterin C4bC2a C1inh CD59 C3bBb C3 C4 C1 C2 C5 C6 C7 C8 C9 0.6 mg/ml 1.3 mg/ml

  12. FUNCTION C3b > C4b CR1 iC3b > iC4b CR3 C3d > C4d CR2

  13. C4d vs C3d STAINING

  14. C4d Deposition ATGAM vs Thymoglobulin C4d+ / Total ATGAM 9 / 9 (Horse polyclonal) Thymoglobulin 0 / 8 (Rabbit polyclonal)

  15. C Reactive Protein Activation of Complement

  16. ANTIBODY ASSOCIATED REJECTION 7 years after transplantation anti-DR7 and DRw53

  17. ANTIBODY ASSOCIATED REJECTION after plasmapheresis plus IVIg anti-DR7 and DRw53 undetectable C4d C3d

  18. Clearance of iC3b and C3d from Human Endothelial Cells in vitro

  19. LEUKOCYTE ACTIVATION BY “SUBLYTIC” MAC

  20. ACTIVATION OF ENDOTHELIAL CELL BY MAC MAC W-P Endothelial

  21. ACTIVATION OF ENDOTHELIAL CELL BY MAC MAC CD63 vWf P-selectin Retraction Endothelial Tissue Factor

  22. ACTIVATION OF ENDOTHELIAL CELL BY MAC MAC PAF CD63 vWf P-selectin MCP-1 Synthesis Tissue IL-8 Factor Retraction Endothelial P-selectin Tissue Factor bFGF PDGF

  23. Monocyte/ P-selectin bFGF Macrophage MAC PDGF Patelet vWf Tissue TNFa CD63 vWf PAF Factor P-selectin MCP-1 Synthesis Tissue IL-8 Factor Retraction Endothelial P-selectin Tissue Factor bFGF PDGF

  24. vWf B. Wasowska et al 2001 Transplantation 71, 727.

  25. Ig Knock Out Recipients

  26. Operating Characteristics of ANA Immunofluorescence Assays 1:40 1:80 1:160 1:320 Tan et al. Arth & Rheum 40: 1601-1611, 1997

  27. HUMORAL IMMUNITY IN CARDIAC TRANSPLANTS Cardiac Surgery: J. Conte Cardiology: D Carter, EK Kasper, D Judge Immunogenetics: D Lucas, MS Leffell, AA Zachary Bioengineering: J Haun, R Alevriadou Pathology: RH Hruban, ER Rodriguez, WM Baldwin III

More Related